Last quarter (Q4 2023), China Jo-Jo Drugstores's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q4, China Jo-Jo Drugstores's net income was $―. See China Jo-Jo Drugstores’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Total Revenue	-	$ 148.81M	$ 164.39M	$ 133.13M	$ 117.33M	$ 107.55M
Cost of Revenue	-	$ 114.53M	$ 127.87M	$ 103.89M	$ 91.80M	$ 82.44M
Gross Profit	-	$ 34.28M	$ 36.52M	$ 29.24M	$ 25.53M	$ 25.11M
Operating Expense	-	$ 55.21M	$ 39.21M	$ 37.85M	$ 31.90M	$ 25.98M
Operating Income	-	$ 93.61M	$ 125.33M	$ -8.61M	$ -6.38M	$ -876.13K
Net Non Operating Interest Income Expense	-	$ -1.50M	$ 139.70K	$ 252.69K	$ 365.23K	$ 112.89K
Other Income Expense	-	$ -1.68M	$ -455.55K	$ 12.10K	$ -431.10K	$ -419.76K
Pretax Income	-	$ -20.74M	$ -2.10M	$ -8.34M	$ -6.44M	$ -1.18M
Tax Provision	-	$ 394.54K	$ 1.10M	$ 31.64K	$ 16.26K	$ 134.76K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	$ -21.14M	$ -3.19M	$ -8.12M	$ -5.81M	$ -926.28K
Basic EPS	-	$ -2.07	$ -11.04	$ -2.40	$ -0.18	$ -0.03
Diluted EPS	-	$ -2.07	$ -11.04	$ -2.40	$ -0.18	$ -0.03
Basic Average Shares	-	$ 10.20M	$ 289.94K	$ 3.40M	$ 32.82M	$ 28.94M
Diluted Average Shares	-	$ 10.20M	$ 289.94K	$ 3.40M	$ 32.82M	$ 28.94M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	$ 169.74M	$ 167.09M	$ 141.74M	$ 123.70M	$ 108.43M
Net Income From Continuing And Discontinued Operation	-	$ -21.14M	$ -3.19M	$ -8.12M	$ -5.81M	$ -926.28K
Normalized Income	-	$ -8.56M	$ -1.36M	$ -7.96M	$ -5.59M	$ -681.44K
Interest Expense	-	-	-	$ 455.19K	$ 698.52K	$ 0.00
EBIT	-	$ -21.56M	$ -2.24M	$ -7.89M	$ -5.74M	$ -1.18M
EBITDA	-	$ -20.84M	$ -981.85K	$ -6.14M	$ -3.66M	$ 493.41K

Currency in USD

China Jo-Jo Drugstores Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing